Business
Portfolio PDS Biotechnology presents at BIO 2016
Portfolio PDS Biotechnology presents at BIO 2016.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 3753A NetScientific PLC 07 June 2016 \n\n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\nNetScientific Portfolio PDS Biotechnology presents at BIO 2016\nNetScientific makes further investment in PDS Biotechnology\nLondon, UK - 7 June 2016 - NetScientific plc (AIM: NSCI), the transatlantic healthcare technology group, is pleased to note that its therapeutics portfolio company, PDS Biotechnology, will today be presenting at BIO 2016 in San Francisco, California. Frank Bedu-Addo, CEO of PDS Biotechnology, will discuss the recently announced positive results for the Phase I human clinical trial as well as PDS's plans for upcoming Phase 2 clinical trials in several HPV-related cancers, including cervical cancer, head and neck cancers and intra-epithelial neoplasias as well as prostate, ovarian, breast and colorectal cancer. \nIn addition, further to the Company's announcement of 13 April 2016, NetScientific can confirm that it has invested a further $500,000 in PDS Biotechnology. This investment has been made by way of a convertible loan, and the funding will be used to assist in the implementation of its Phase 2 programmes.\nCommenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: \"The promising results from PDS's Phase II results have provided positive validation of the Versamune® T-cell activating platform technology. We now look forward to continuing our support of this exciting portfolio company as is looks to further corroborate the potential of PDS0101 in Phase II development.\"\nThe full text of the announcement from PDS Biotechnology can be found below.\nFor more information, please contact:\n\n\n\n\nNetScientific\nFrançois R. Martelet, M.D., CEO\nMark Nanovich, Interim CFO\n \n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\nInvestec (NOMAD and broker)\nGary Clarence / Daniel Adams\n\n\nTel: +44 (0)20 7597 4000\n\n\n\n\nConsilium Strategic Communications\nMary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton\n\n\n \nTel: +44 (0)20 3709 5700\[email protected]\n\n\n\n\n \nAbout NetScientific\nNetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health...